IPSEN Toevoegen aan een lijst
|
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
| 106,3 EUR | -0,09% |
|
-2,83% | -1,48% |
Vakgebied
- oncologie (75,1%);
- neurowetenschap (21,1%);
- zeldzame ziekten (3,7%).
Eind 2023 had de groep 4 onderzoeks- en ontwikkelingscentra in Frankrijk, het Verenigd Koninkrijk, de Verenigde Staten en China, en 4 productiesites wereldwijd.
De geografische verdeling van de omzet is als volgt: Europa (40,2%), Noord-Amerika (33,3%) en andere (26,5%).
Aantal werknemers: 5 325
Verkoop per activiteit
| EUR in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
|---|---|---|---|---|---|
Oncology
75,2
%
| 2 380 | 78,7 % | 2 351 | 75,2 % | -1,19% |
Neurosciences
21,1
%
| 604 | 20,0 % | 659 | 21,1 % | +9,08% |
Rare Diseases
3,7
%
| 41 | 1,4 % | 117 | 3,7 % | +184,43% |
Verkoop per regio
| EUR in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
|---|---|---|---|---|---|
Europe
40,2
%
| 1 237 | 40,9 % | 1 257 | 40,2 % | +1,56% |
North America
33,3
%
| 1 032 | 34,1 % | 1 042 | 33,3 % | +0,94% |
Rest of the World
26,5
%
| 756 | 25,0 % | 829 | 26,5 % | +9,73% |
Managers
| Managers | Titel | Leeftijd | Van |
|---|---|---|---|
David Loew
CEO | Chief Executive Officer | 57 | 01-07-20 |
| Director of Finance/CFO | 54 | 03-11-14 | |
| Chairman | 66 | 22-11-10 | |
Sandra Silvestri
CTO | Chief Tech/Sci/R&D Officer | 50 | 05-05-23 |
| Chief Tech/Sci/R&D Officer | 57 | 22-09-23 | |
Aidan Murphy
CTO | Chief Tech/Sci/R&D Officer | 58 | 01-01-18 |
Craig Marks
IRC | Investor Relations Contact | - | - |
| Corporate Officer/Principal | - | 01-03-22 | |
| Corporate Officer/Principal | - | 01-10-20 | |
| Corporate Officer/Principal | 50 | 01-11-21 |
Besturend
| Besturend | Titel | Leeftijd | Van |
|---|---|---|---|
Margaret Liu
BRD | Director/Board Member | 66 | 07-06-17 |
Karen Witts
BRD | Director/Board Member | 61 | 21-01-22 |
Michèle Ollier
BRD | Director/Board Member | 65 | 27-05-15 |
| Chairman | 66 | 22-11-10 | |
Henri Beaufour
BRD | Director/Board Member | 59 | 30-08-05 |
Antoine Flochel
BRD | Director/Board Member | 59 | 30-08-05 |
Piet Wigerinck
BRD | Director/Board Member | 58 | 01-05-18 |
David Loew
CEO | Chief Executive Officer | 57 | 01-07-20 |
| Director/Board Member | 44 | 06-11-20 | |
Naomi Binoche
BRD | Director/Board Member | - | - |
Aandelenklasse
| Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
|---|---|---|---|---|---|
| Aandeel A | 1 | 83 814 526 | 34 798 107 ( 41,52 %) | 1 175 285 ( 1,402 %) | 41,52 % |
Participaties
Bedrijfsgegevens
Bedrijven van de groep
| Naam | Categorie en sector |
|---|---|
Ipsen Pharma SAS
 Ipsen Pharma SAS Pharmaceuticals: MajorHealth Technology Ipsen Pharma SAS is a biopharmaceutical company that develops medicines in oncology, neuroscience and rare diseases. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France. |
Pharmaceuticals: Major
|
Ipsen Pharma Biotech SAS
 Ipsen Pharma Biotech SAS Pharmaceuticals: MajorHealth Technology Ipsen Pharma Biotech SAS engages in the pharmaceutical industry. It offers drugs to treat neurology, endocrinology, uro-oncology, hematology, gastroenterology, cardiovascular, and cognitive disorders. The company is headquartered in Signes, France. |
Pharmaceuticals: Major
|
Socapharma SAS
|
Sector
Verkoop per activiteit
Verkoop per regio
Trading rating
Beleggingsrating
ESG Refinitiv
B+
Verkoop
Koop
Gemiddeld advies
Accumuleren
Aantal analisten
15
Laatste slotkoers
106,3
EUR
Gemiddelde koersdoel
124,6
EUR
Spread / Gemiddelde doel
+17,24%
Herzieningen van WPA
| Vaira. 1 jan. | Kapi. | |
|---|---|---|
| -1,48% | 9,35 mld. | |
| +27,97% | 676 mld. | |
| +23,58% | 554 mld. | |
| -7,02% | 349 mld. | |
| +14,85% | 318 mld. | |
| +6,25% | 291 mld. | |
| +2,96% | 210 mld. | |
| -0,41% | 204 mld. | |
| -10,02% | 194 mld. | |
| -11,81% | 144 mld. |
